Article
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Cancer science - 1 Sept 2015
Kato Terufumi, Yoshioka Hiroshige, Okamoto Isamu, Yokoyama Akira, Hida Toyoaki, Seto Takashi, Kiura Katsuyuki, Massey Dan, Seki Yoko, Yamamoto Nobuyuki
Abstract excerpt
In LUX-Lung 3, afatinib significantly improved progression-free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation-positive lung adenocarcinoma patients and overall survival (OS) in Del19 patients. Preplanned analyses in Japanese patients from LUX-Lung 3 were performed. Patients were randomized 2:1 to afatinib or cisplatin/pemetrexed, stratified by mutation type (Del19/L858R/Other). Primary endpoint was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.